BACKGROUND: Hepatocyte growth factor (HGF) is an endothelium specific growth factor that has been implicated in angiogenesis, a crucial event for the development of proliferative diabetic retinopathy (PDR). The aim of the study is to determine the intravitreous concentrations of HGF in diabetic patients with PDR, and to investigate whether its serum levels could contribute to its intravitreous concentration. METHODS: 17 diabetic patients and seven non-diabetic patients in whom a vitrectomy was performed were studied. Both groups were matched by serum levels of HGF. Venous blood and vitreous samples were collected simultaneously at the time of vitreoretinal surgery. Vitreous and serum HGF were determined by ELISA. RESULTS: Intravitreous concentrations of HGF (median and range) were higher in diabetic patients (17.04 ng/ml (9.98-80)) in comparison with non-diabetic patients (5.88 ng/ml (2.57-14.20); p=0. 003). Intravitreous HGF concentrations were strikingly higher than serum HGF concentrations both in diabetic patients (17.04 ng/ml (9. 98-80) v 0.66 ng/ml (0.26-1.26); p<0.001) and in the control group (5.88 ng/ml (2.57-14.20) v 0.68 ng/ml (0.49-0.96); p=0.003). No correlation was found between serum and vitreous levels of HGF in both groups (diabetic patients, r= -0.31; p=0.5 and control subjects r= -0.15; p=0.5). CONCLUSION: The high vitreous levels of HGF observed in diabetic patients with PDR cannot be attributed to serum diffusion across the blood-retinal barrier. Therefore, intraocular synthesis appears to be the main contributing factor for the high vitreous HGF concentrations in diabetic patients, a cytokine that seems to be directly involved in the pathogenesis of PDR.
BACKGROUND:Hepatocyte growth factor (HGF) is an endothelium specific growth factor that has been implicated in angiogenesis, a crucial event for the development of proliferative diabetic retinopathy (PDR). The aim of the study is to determine the intravitreous concentrations of HGF in diabeticpatients with PDR, and to investigate whether its serum levels could contribute to its intravitreous concentration. METHODS: 17 diabeticpatients and seven non-diabeticpatients in whom a vitrectomy was performed were studied. Both groups were matched by serum levels of HGF. Venous blood and vitreous samples were collected simultaneously at the time of vitreoretinal surgery. Vitreous and serum HGF were determined by ELISA. RESULTS: Intravitreous concentrations of HGF (median and range) were higher in diabeticpatients (17.04 ng/ml (9.98-80)) in comparison with non-diabeticpatients (5.88 ng/ml (2.57-14.20); p=0. 003). Intravitreous HGF concentrations were strikingly higher than serum HGF concentrations both in diabeticpatients (17.04 ng/ml (9. 98-80) v 0.66 ng/ml (0.26-1.26); p<0.001) and in the control group (5.88 ng/ml (2.57-14.20) v 0.68 ng/ml (0.49-0.96); p=0.003). No correlation was found between serum and vitreous levels of HGF in both groups (diabeticpatients, r= -0.31; p=0.5 and control subjects r= -0.15; p=0.5). CONCLUSION: The high vitreous levels of HGF observed in diabeticpatients with PDR cannot be attributed to serum diffusion across the blood-retinal barrier. Therefore, intraocular synthesis appears to be the main contributing factor for the high vitreous HGF concentrations in diabeticpatients, a cytokine that seems to be directly involved in the pathogenesis of PDR.
Authors: Y Nakamura; R Morishita; J Higaki; I Kida; M Aoki; A Moriguchi; K Yamada; S Hayashi; Y Yo; H Nakano; K Matsumoto; T Nakamura; T Ogihara Journal: J Hypertens Date: 1996-09 Impact factor: 4.844
Authors: M Nishimura; K Nakano; M Ushiyama; A Nanbu; K Ohtsuka; H Takahashi; M Yoshimura Journal: J Clin Endocrinol Metab Date: 1998-01 Impact factor: 5.958
Authors: R Morishita; S Nakamura; Y Nakamura; M Aoki; A Moriguchi; I Kida; Y Yo; K Matsumoto; T Nakamura; J Higaki; T Ogihara Journal: Diabetes Date: 1997-01 Impact factor: 9.461
Authors: Q Li; J Weng; R R Mohan; G L Bennett; R Schwall; Z F Wang; K Tabor; J Kim; S Hargrave; K H Cuevas; S E Wilson Journal: Invest Ophthalmol Vis Sci Date: 1996-04 Impact factor: 4.799
Authors: Alexander V Ljubimov; Sergio Caballero; Annette M Aoki; Lorenzo A Pinna; Maria B Grant; Raquel Castellon Journal: Invest Ophthalmol Vis Sci Date: 2004-12 Impact factor: 4.799
Authors: John A Kessler; Aziz Shaibani; Christine N Sang; Mark Christiansen; David Kudrow; Aaron Vinik; Nari Shin Journal: Clin Transl Sci Date: 2021-02-02 Impact factor: 4.689
Authors: Christoph Ehlken; Bastian Grundel; Daniel Michels; Bernd Junker; Andreas Stahl; Günther Schlunck; Lutz L Hansen; Nicolas Feltgen; Gottfried Martin; Hansjürgen T Agostini; Amelie Pielen Journal: PLoS One Date: 2015-05-15 Impact factor: 3.240